Published in J Neurovirol on February 01, 2010
Syphilis: using modern approaches to understand an old disease. J Clin Invest (2011) 1.58
Incidence of Co-Infections of HIV, Herpes Simplex Virus Type 2 and Syphilis in a Large Cohort of Men Who Have Sex with Men in Beijing, China. PLoS One (2016) 0.75
Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD AIDS (2013) 0.75
Microglia: a sensor for pathological events in the CNS. Trends Neurosci (1996) 12.00
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS (2004) 4.17
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med (1997) 4.11
Alteration in the natural history of neurosyphilis by concurrent infection with the human immunodeficiency virus. N Engl J Med (1987) 4.10
Update on syphilis: resurgence of an old problem. JAMA (2003) 3.31
Syphilis and HIV: a dangerous combination. Lancet Infect Dis (2004) 3.09
Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol (1997) 2.92
Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis (2004) 2.59
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis (2004) 2.23
The re-emergence of syphilis in the United Kingdom: the new epidemic phases. Sex Transm Dis (2005) 2.21
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis (1997) 1.90
Neurosyphilis in the modern era. J Neurol Neurosurg Psychiatry (2004) 1.55
Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS (1999) 1.50
AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. J Infect (2004) 1.42
Central nervous system microglial cell activation and proliferation follows direct interaction with tissue-infiltrating T cell blasts. J Immunol (1998) 1.17
Effect of genital ulcer disease on HIV-1 coreceptor expression in the female genital tract. J Infect Dis (2007) 1.06
Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis (2007) 1.05
Syphilis and HIV co-infection: when is lumbar puncture indicated? Curr HIV Res (2005) 1.01
Syphilis and human immunodeficiency virus co-infection. J Natl Med Assoc (2003) 0.97
High prevalence of syphilis-HIV co-infection at four hospitals of the city of Buenos Aires, Argentina. Rev Argent Microbiol (2006) 0.91
Evaluation of syphilis in patients with HIV infection in Nigeria. Trop Med Int Health (2005) 0.90
Increasing intrathecal lymphocytosis and immunoglobulin G production in neurologically asymptomatic HIV-1 infection. J Neuroimmunol (1988) 0.87
Partners in crime: co-infections in the developing world. Clin Exp Immunol (2000) 0.82
Neurocognitive impairment in human immunodeficiency virus infection is correlated with sexually transmitted disease history. Sex Transm Dis (1997) 0.80
Immune surveillance and autoantigen recognition in the central nervous system. Aust N Z J Med (1995) 0.80
The great pox. Clin Infect Dis (2004) 0.79
[The impact of HIV infection on the incidence of syphilis and gonorrhea at a university hospital (1985-1994)]. Medicina (B Aires) (1997) 0.78
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol (2004) 5.18
Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol (2004) 3.12
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment. AIDS (2004) 2.55
The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up. J Am Acad Child Adolesc Psychiatry (2013) 2.48
Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis (2011) 2.44
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS (2005) 2.25
Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis (2003) 2.16
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (2011) 1.90
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology (2013) 1.88
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol (2011) 1.73
Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol (2007) 1.73
Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS (2013) 1.71
Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J Neurovirol (2008) 1.64
Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis (2007) 1.63
Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol (2005) 1.62
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60
The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS (2005) 1.55
Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS (2004) 1.53
Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS (2013) 1.51
Markers of macrophage activation and axonal injury are associated with prospective memory in HIV-1 disease. Cogn Behav Neurol (2006) 1.47
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients. J Acquir Immune Defic Syndr (2003) 1.44
HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis (2010) 1.40
Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals. J Clin Exp Neuropsychol (2006) 1.33
Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol (2011) 1.31
Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep (2011) 1.26
Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol (2003) 1.22
Synergistic effects of HIV infection and older age on daily functioning. J Acquir Immune Defic Syndr (2012) 1.21
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother (2010) 1.19
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology (2015) 1.18
Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology (2007) 1.16
Lithium improves HIV-associated neurocognitive impairment. AIDS (2006) 1.16
Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol (2005) 1.15
Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol (2006) 1.14
Neurobehavioral effects of HIV-1 infection in China and the United States: a pilot study. J Int Neuropsychol Soc (2007) 1.12
APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. AIDS (2010) 1.12
Are HIV care providers talking with patients about safer sex and disclosure?: A multi-clinic assessment. AIDS (2002) 1.09
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol (2008) 1.08
Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug Alcohol Depend (2009) 1.08
Prevalence and factors associated with sleep disturbances among early-treated HIV-infected persons. Clin Infect Dis (2012) 1.06
Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J Neurovirol (2009) 1.06
HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence. AIDS Behav (2012) 1.06
Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc (2003) 1.06
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis (2013) 1.05
NeuroAIDS in Africa. J Neurovirol (2010) 1.05
Role of metabolic syndrome components in human immunodeficiency virus-associated stroke. J Neurovirol (2009) 1.01
Test-retest stability of calibrated BOLD-fMRI in HIV- and HIV+ subjects. Neuroimage (2010) 1.00
Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria. J Neurovirol (2012) 1.00
Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer. J Neurovirol (2013) 0.99
Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS. J Neuroimmune Pharmacol (2007) 0.98
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother (2010) 0.98
Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology (2013) 0.95
The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol (2004) 0.95
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS (2009) 0.95
Use of erectile dysfunction medication and unsafe sex among HIV+ men who have sex with men in care. Int J STD AIDS (2005) 0.94
Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med (2002) 0.94
Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr (2013) 0.93
Effect of a brief antiretroviral adherence intervention delivered by HIV care providers. J Acquir Immune Defic Syndr (2005) 0.93
Adjuvanted influenza vaccines. Expert Rev Vaccines (2013) 0.93
Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration. Open AIDS J (2007) 0.93
CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol (2004) 0.92
Global NeuroAIDS roundtable. J Neurovirol (2013) 0.92
The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol (2007) 0.91
Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. AIDS (2011) 0.91
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother (2012) 0.90
Incidence of post-dural puncture headache in research volunteers. Headache (2011) 0.90
Scanning laser polarimetry demonstration of retinal nerve fiber layer damage in human immunodeficiency virus-positive patients without infectious retinitis. Retina (2007) 0.89
Approaches to identifying appropriate medication adherence assessments for HIV infected individuals with comorbid bipolar disorder. AIDS Patient Care STDS (2012) 0.89
Molecular epidemiology of HIV-1 clades in Southern Brazil. Mem Inst Oswaldo Cruz (2010) 0.89
Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy. Clin Infect Dis (2002) 0.88
Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings. J Int Neuropsychol Soc (2010) 0.88
Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies. J Neurovirol (2011) 0.88
NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in mice. PLoS One (2013) 0.87
Recurrent Kawasaki disease-like syndrome in a patient with acquired immunodeficiency syndrome. Clin Infect Dis (2002) 0.87
Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation. J Acquir Immune Defic Syndr (2015) 0.86
Valproic acid does not affect markers of human immunodeficiency virus disease progression. J Neurovirol (2006) 0.86